NEUROCRINE BIOSCIENCES INC Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
NEUROCRINE BIOSCIENCES INC (NBIX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $13.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-11
- NEUROCRINE BIOSCIENCES INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $13.60M.
- NEUROCRINE BIOSCIENCES INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was -$20.40M.
- NEUROCRINE BIOSCIENCES INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was -$3.90M.
- NEUROCRINE BIOSCIENCES INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was -$2.50M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $13.60M 10-K · filed 2026-02-11 | |
| 2024-12-31 | -$20.40M 10-K · filed 2026-02-11 | |
| 2023-12-31 | -$3.90M 10-K · filed 2026-02-11 | |
| 2022-12-31 | -$2.50M 10-K · filed 2025-02-10 | |
| 2021-12-31 | -$11.30M 10-K · filed 2024-02-09 | |
| 2020-12-31 | -$6.70M 10-K · filed 2023-02-09 | |
| 2019-12-31 | -$12.80M 10-K · filed 2022-02-11 | -$12.79M 10-K · filed 2020-02-07 |
| 2018-12-31 | -$9.80M 10-K · filed 2021-02-05 | -$9.78M 10-K · filed 2019-02-08 |
| 2017-12-31 | -$19.59M 10-K · filed 2020-02-07 | |
| 2016-12-31 | -$5.08M 10-K · filed 2019-02-08 | |
| 2015-12-31 | $201.00K 10-K · filed 2018-02-13 | |
| 2014-12-31 | $91.00K 10-K · filed 2017-02-14 | |
| 2013-12-31 | $215.00K 10-K · filed 2016-02-11 | |
| 2012-12-31 | $1.15M 10-K · filed 2015-02-09 | |
| 2011-12-31 | $385.00K 10-K · filed 2014-02-11 | |
| 2010-12-31 | $5.21M 10-K · filed 2013-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |